Radioprotective agents for radiation therapy: Future trends

Future Oncology

Volumn 10, Issue 15, 2014, Pages 2345-2357

  Johnke, Roberta M ^a   Sattler, Jennifer A ^b   Allison, Ron R ^c  

^a EAST CAROLINA UNIVERSITY   (United States)

^b Northwestern Oklahoma State University   (United States)

^c 21ST CENTURY ONCOLOGY   (United States)

Author keywords

antioxidants; free radical scavengers; growth factors; radiation mitigators; radiation therapy; radioprotection

Indexed keywords

AEOL 10150; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIOXIDANT; APOPTOSIS INHIBITOR; CAPTOPRIL; CYSTEINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTOLIMOD; EUK 189; EUK 207; GENISTEIN; GRAMICIDIN S; GROWTH FACTOR; IMISOPASEM MANGANESE; JP 4 039; MERCAPTAMINE; NITROXIDE DERIVATIVE; PALIFERMIN; PENTOXIFYLLINE; RADIOPROTECTIVE AGENT; SCAVENGER; SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE MIMETIC; TEMPOL; TEMPOL H; THIOL DERIVATIVE; TOCOPHEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN INJURY; CANCER RADIOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSESTHESIA; ERYTHEMA; ESOPHAGITIS; HUMAN; HYPOTENSION; LUNG FIBROSIS; LUNG INJURY; MUCOSA INFLAMMATION; NAUSEA; NEPHRITIS; NONHUMAN; RADIATION INDUCED FIBROSIS; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION PROTECTION; RADIOSENSITIVITY; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEIZURE; SKIN EDEMA; STRUCTURE ACTIVITY RELATION; TASTE DISORDER; TISSUE SPECIFICITY; TONGUE DISEASE; VOMITING; XEROSTOMIA;

EID: 84919977168     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.175     Document Type: Review

References (93)

1. Bourgier C, Levy A, Vozenin MC, Deutsch E. Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics? Cancer Metastasis Rev. 31(3-4), 699-712 (2012).
2. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krisha MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 15, 360-371 (2010).
3. Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug Discov. Today 12(19-20), 794-805 (2007).
4. Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin. Radiat. Oncol. 17, 141-148 (2007).
5. Brizel DM, Wasserman TH, Henke M et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin. Oncol. 18(19), 3339-3345 (2000).
6. Koukourakis MI, Kyrias G, Kakolyris S et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized Phase II study. J. Clin. Oncol. 18(11), 2226-2233 (2000).
7. Gauter-Fleckenstein B, Fleckenstein K, Owzar K et al. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic. Biol. Med. 44, 982-989 (2008).
8. Rabbani ZN, Batinic-Haberle I, Anscher MS et al. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int. J. Radiat. Oncol. Biol. Phys. 67, 573-580 (2007).
9. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation induced injury. Free Radic. Biol. Med. 33, 857-863 (2002).
10. Rosenthal RA, Fish B, Hill RP et al. Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med. Chem. 11(4), 359-372 (2011).
11. Mitchell JB, DeGraff W, Kaufman D et al. Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch. Biochem. Biophys. 289(1), 62-70 (1991).
12. Hahn SM, Tochner Z, Krishna CM et al. Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 52(7), 1750-1753 (1992).
13. Metz JM, Smith D, Mick R et al. A Phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin. Cancer Res. 10(19), 6411-6417 (2004).
14. Calveley VL, Jelveh S, Langan A et al. Genistein can mitigate the effect of radiation on rat lung tissue. Radiat. Res. 173(5), 602-611 (2010).
15. Landauer MR, Srinivasan V, Seed TM. Genistein treatment protects mice from ionizing radiation injury. J. Appl. Toxicol. 23, 379-385 (2003).
16. Davis TA, Mungunsukh O, Zins S, Day RM, Landauer MR. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int. J. Radiat. Biol. 84(9), 713-726 (2008).
17. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-2598 (2004).
18. Vadhan-Raj S, Goldberg JD, Perales MA. Berger DP, van den Brink MR. Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J. Cell. Mol. Med. 17(11), 1371-1384 (2013).
19. Robbins ME, Zhao W, Garcia-Espinosa MA et al. Renin-angiotensin system blockers and modulation of radiation-induced brain injury. Curr. Drug Targets 11, 1413-1422 (2010).
20. Wang H, Liao Z, Zhuang Y et al. Do angiotensin-converting enzyme inhibitors reduce the risk of symptomatic radiation pneumonitis in patients with non-small cell lung cancer after definitive radiation therapy? Analysis of a single-institution database. Int. J. Radiat. Oncol. Biol. Phys. 87(5), 1071-1077 (2013).
21. Wang LW, Fu XL, Clough R et al. Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis? Radiat. Res. 153(4), 405-410 (2000).
22. Burdelya LG, Krivokrysenko VI, Tallant TC et al. Anagonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008).
23. Wang ZD, Qiao YL, Tian XF et al. Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis. Asian Pac J. Cancer Prev. 13, 4763-4767 (2012).
24. Hall EJ. DNA strand breaks and chromosomal aberrations. In: Radiobiology for the Radiologist (5th Edition). EJ Hall (Ed.). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 17-31 (2000).
25. Koukourakis MI. Radiation damage and radioprotectants: new concepts in the area of molecular medicine. Br. J. Radiol. 85, 313-330 (2012).
26. Andersen MH, Becker JC, Straten PT. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat. Rev. Drug Discov. 4(5), 399-409 (2005).
27. Maier P, Wenz F, Herskind C. Radioprotection of normal tissue cells. Strahlenther. Onkol. 190(8), 745-752 (2014).
28. Weiss JF, Landauer MR. History and development of radiation-protective drugs. Int. J. Radiat. Biol. 85(7), 539-573 (2009).
29. Patt HM, Tyree EB, Straube RL, Smith DE. Cysteine protection against X irradiation. Science 110, 213-214 (1949).
30. Yuhas JM, Storer JB. Chemoprotection against three modes of radiation death in the mouse. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 15, 233-237 (1969).
31. Kang SK, Rabbani ZN, Folz RJ, et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 57, 1056-1066 (2003).
32. Moding EJ, Kastan MB, Kirsch DG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 12(7), 526-542 (2013).
33. Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother. Oncol. 32(1), 12-20 (1994).
34. Greenberger JS, Clump D, Valerian K et al. Strategies for discovery of small molecule radiation protectors and radiation mitigators. Front. Oncol. 1, 59 (2012).
35. Edsmyr F, Huber W, Menander KB. Orgotein efficacy in ameliorating side effects due to radiation therapy. I. Double-blind, placebo-controlled trial in patients with bladder tumors. Curr. Ther. Res. Clin. Exp. 19, 198-211 (1976).
36. Marberger H, Bartsch G, Huber W et al. Orgotein: a new drug for the treatment of radiation cystitis. Curr. Ther. Res. Clin. Exp. 18, 466-475 (1975).
37. Huang X, Song C1, Zhong C, Wang F. Research progress in the radioprotective effect of superoxide dismutase. Drug Discov. Ther. 6(4), 169-177 (2012).
38. Greenberger JS, Epperly MW. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In Vivo 21, 141-146 (2007).
39. Epperly MW, Defilippi S, Sikora C, Gretton J, Kalend A, Greenberger JS. Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthopedic tumors from irradiation. Gene Ther. 7, 1011-1018 (2000).
40. Guo H, Seixas-Silva JA Jr, Epperly MW et al. Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat. Res. 159, 361-370 (2003).
41. Epperly MW, Kagan VE, Sikora CA et al. Manganese superoxide dismutase-plasmid/ liposome (MnSOD-PL) administration protects mice from esophagitis associated with fractionated radiation. Int. J. Cancer 96, 221-231 (2001).
42. Epperly MW, Carpenter M, Agarwal A, Mitra P, Nie S, Greenberger JS. Intraoral manganeses superoxide dismutase-plasmid/ liposome (MnSOD-PL) radioprotective gene therapy decreases ionizing irradiation-induced murine mucosal cell cycling and apoptosis. In Vivo 18, 401-410 (2004).
43. Epperly, M.W. Wegner R, Kanai AJ et al. Effects of MnSOD-plasmid liposome gene therapy on antioxidant levels in irradiated murine oral cavity orthopedic tumors. Radiat. Res. 167, 289-297 (2007).
44. Murphy CK, Fey EG, Watkins BA et al. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clin. Cancer Res. 14, 4292-4297 (2008).
45. Hahn SM, Krishna MC, DeLuca AM, Coffin D, Mitchell JB. Evaluation of the hydroxylamine tempol-H as an in vivo radioprotector. Free Radic. Biol. Med. 28(6), 953-958 (2000).
46. Soule BP, Hyodo F, Matsumoto K-I et al. The chemistry and biology of nitroxide compounds. Free Radic. Biol. Med. 42(11), 1632-1650 (2007).
47. Goff JP, Epperly MW, Dixon T et al. Radiobiologic effects of GS-nitroxide (JP4-039) on the hematopoietic syndrome. In Vivo 25, 315-323 (2011).
48. Epperly MW, Goff JP, Li S et al. Intraesophageal administration of GS-nitroxide (JP4-039) protects against ionizing irradiation-induced esophagitis. In Vivo 24, 811-819 (2010).
49. Giardi MT, Touloupakis E, Bertolotto D, Mascetti G Preventive or potential therapeutic value of nutraceuticals against ionizing radiation-induced oxidative stress in exposed subjects and frequent fliers. Int. J. Mol. Sci. 14, 17168-17192 (2013).
50. Sminia P, van der Kracht AH, Frederiks WM, Jansen W. Hyperthermia, radiation carcinogenesis and the protective potential of vitamin A and N-acetylcysteine. J. Cancer Res. Clin. Oncol. 122, 343-350 (1996).
51. Cekan E, Tribukait B, Vokal-Borek DH. Protective effect of selenium against radiation induced malformations in mice. Acta Radiol. Oncol. 24, 267-271 (1985).
52. Kennedy AR, Krinsky NI. Effects of retinoids, carotene and canthaxanthene on U.V. and X-ray-induced transformation of C3H10T 1/2 cells in vitro. Nutr. Cancer 22, 219-232 (1994).
53. Konopacka M, Widel M, Rzeszowska-Wolny J. Modifying effect of vitamins C, E and beta-carotene against gamma-ray induced DNA damage in mouse cells. Mutat. Res. 417, 85-94 (1998).
54. Mutlu-Turkoglu U, Erbil Y, Oztezcan S, Olgac V, Toker G, Uysal M. The effect of selenium and/or vitamin E treatments on radiation-induced intestinal injury in rats. Life Sci. 66, 1905-1913 (2000).
55. Harapanhalli RS, Yaghmai V, Giuliani D, Howell RW, Rao DV. Antioxidant effects of vitamin C in mice following X-irradiation. Res. Commun. Mol. Pathol. Pharmacol. 94, 271-287 (1996).
56. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int. J. Radiat. Oncol. Biol. Phys. 72, 170-177 (2008).
57. Sieber F, Muir SA, Cohen EP et al. High-dose selenium for the mitigation of radiation injury: a pilot study in a rat model. Radiat. Res. 171, 368-373 (2009).
58. Mills EE. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Br. J. Cancer 57, 416-417 (1998).
59. Bairati I, Meyer F, Gélinas M et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J. Clin. Oncol. 23, 5805-5813 (2005).
60. Meyer F, Bairati I, Fortin A et al. Interaction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int. J. Cancer 122, 1679-1683 (2008).
61. Blickenstaff RT, Brandstadter SM, Reddy S et al. Potential radioprotective agents. 1. Homologs of melatonin. J. Pharm. Sci. 83, 216-218 (1994).
62. Vijayalaxmi, Meltz ML, Reiter RJ et al. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat. Res. 425, 21-27 (1999).
63. Topkan E, Tufan H, Yavuz AA et al. Comparison of the protective effects of melatonin and amifostine on radiation-induced epiphyseal injury. Int. J. Radiat. Biol. 84, 796-802 (2008).
64. Manda K, Ueno M, Anzai K. Cranial irradiation-induced inhibition of neurogenesis in hippocampal dentate gyrus of adult mice: attenuation by melatonin pretreatment. J. Pineal Res. 46, 71-78 (2009).
65. Hussein MR, Abu-Dief EE, Kamel E et al. Melatonin and roentgen irradiation-induced acute radiation enteritis in Albino rats: an animal model. Cell Biol. Int. 32, 1353-1361 (2008).
66. Manda K, Anzai K, Kumari S et al. Melatonin attenuates radiation-induced learning deficit and brain oxidative stress in mice. Acta Neurobiol. Exp. (Wars) 267, 63-70 (2007).
67. Akagi T, Ushinohama K, Ikesue S et al. Chronopharmacology of melatonin in mice to maximize the antitumor effect and minimize the rhythm disturbance effect. J. Pharmacol. Exp. Ther. 308, 378-384 (2004).
68. Berk L, Berkey B, Rich T et al. Randomized phase II trial of high-dose melatonin and radiationtherapy for RPA class 2 patients with brain metastases (RTOG 0119). Int. J. Radiat. Oncol. Biol. Phys. 68, 852-857 (2007).
69. Hillman GG, Singh-Gupta V, Lonardo F et al. Radioprotection of lung tissue by soy isoflavones. J. Thorac. Oncol. 8(11), 1356-1364 (2013).
70. Cohen EP, Fish BL, Irving AA, Rajapurkar MM, Shah SV, Moulder JE. Radiation nephropathy is not mitigated by antagonists of oxidative stress. Radiat. Res. 172(2), 260-264 (2009).
71. Singh VK, Yadav VS. Role of cytokines and growth factors in radioprotection. Exp. Mol. Pathol. 78(2), 156-169 (2005).
72. Anscher MS, Thrasher B, Zgonjanin L et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 71(3), 829-837 (2008).
73. Dainiak N. Rationale and recommendations for treatment of radiation injury with cytokines. Health Phys. 98(6), 838-842 (2010).
74. Lambin P1, Ramaekers BL, van Mastrigt GA et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst. Rev. 3, CD006158 (2009).
75. Okunieff P, Mester M, Wang J et al. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat. Res. 150, 204-211 (1998).
76. Gonzales J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int. J. Radiat. Oncol. Biol. Phys. 67, 323-326 (2007).
77. Taniguchi CM, Miao YR, Diep AN et al. PHD inhibition mitigates and protects against radiation-induced gastrointestinal toxicity via HIF2. Sci. Transl. Med. 6, 1-9 (2014).
78. Casey-Sawicki K, Zhang M, Kim S et al. A basic fibroblast growth factor analog for protection and mitigation against acute radiation syndromes. Health Phys. 106(6), 704-712 (2014).
79. Brizel DM. Pharmacolgic approaches to radiation protection. J. Clin. Oncol. 25(26), 4084-4089 (2007).
80. Prasanna PG, Stone HB, Wong RS et al. Normal tissue protection for improving radiotherapy: where are the gaps? Transl. Cancer Res. 1(1), 35-48 (2012).
81. Molteni A, Wolfe LF, Ward WF et al. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 13, 1307-1316 (2007).
82. Wang Y, Meng A, Lang H et al. Activation of nuclear factor kappa B in vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res. 64, 6240-6246 (2004).
83. Qiu W, Carson-Walter EB, Liu H et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2(6), 576-583 (2008).
84. Wu WS, Heinrichs S, Xu D et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing PUMA. Cell 123(4), 641-653 (2005).
85. Mustata G, Li M, Zevola N et al. Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. Curr. Top. Med. Chem. 11(3), 281-290 (2011).
86. Maier P, Herskind C, Barzan D, Zeller WJ, Wenz F. SNAI2 as a novel radioprotector of normal tissue by gene transfer using a lentiviral bicis-tronic SIN vector. Radiat. Res. 173, 612-619 (2010).
87. Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG. Preventive intervention possibilities in radiotherapy-and chemotherapy-induced oral mucositis: results of meta-analyses. J. Dent. Res. 85(8), 690-700 (2006).
88. Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J. Clin. Oncol. 29(20), 2808-2814 (2011).
89. Komaki R, Lee JS, Milas L et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int. J. Radiat. Oncol. Biol. Phys. 58(5), 1369-1377 (2004).
90. Lawrence YR, Paulus R, Langer C et al. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer 80(3), 298-305 (2013).
91. Shuette W, Krzakowski MJ, Massuti B et al. Randomized Phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemradiotherapy for locally advanced unresectable non small lung cancer. J. Thorac. Oncol. 7(1), 157-164 (2012).
92. Kharofa J, Cohen EP, Tomic R, Xiang Q, Gore E. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 84(1), 238-243 (2012).
93. Cohen EP, Bedi M, Irving AA et al. Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation. Int. J. Radiat. Oncol. Biol. Phys. 83(1), 292-296 (2012).